Clinical Trials Directory

Trials / Unknown

UnknownNCT05225285

Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents

Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents - Curumim Project

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
1,120 (estimated)
Sponsor
Federal University of Espirito Santo · Academic / Other
Sex
All
Age
3 Years – 49 Years
Healthy volunteers
Accepted

Summary

To evaluate the efficacy and safety of vaccinating children and adolescents, aged 3 to 17 years, with a two-dose schedule of the inactivated vaccine (Coronavac) against SARS-Cov-2.

Detailed description

Nine hundred sixty (960) participants will be randomized into 2 groups, in a 2:1 ratio, to receive the inactivated Coronavac/Butantan vaccine (VACC, N=640) and a group to receive the immunizing BNT162b2 (Pfizer) (BNTC, N=320). The VACC group will also be compared to a group of adults aged 18 to 49 who received Coronavac (ADU, N=160). The main outcome will be the geometric title of neutralizing antibodies and the secondary outcomes will be the incidence of the number of cases confirmed by RT-PCR, the cellular immune response and frequency of adverse events. Outcomes will be evaluated before the first dose, and 28 and 90 days after the second dose, and followup after 6 and 12 months. The study hypothesis is that the cellular and humoral immune response of children and adolescents is not inferior to the age group 18 to 49 years, who received Coronavac and compared to children vaccinated with the immunizing BNT162b2 (Pfizer) and that the inactivated vaccine presents lower reactogenicity for the age group studied.

Conditions

Interventions

TypeNameDescription
BIOLOGICALInactivated Coronavac/Butantan vaccineInactivated Coronavac/Butantan vaccine in 2 doses of 0.5 ml, 4 weeks apart
BIOLOGICALBNT162b2 (Pfizer)BNT162b2 (Pfizer) vaccine in 2 doses of 0.1 ml or 0.30 ml (according to age group), 4 weeks apart

Timeline

Start date
2022-01-21
Primary completion
2022-06-21
Completion
2023-03-21
First posted
2022-02-04
Last updated
2022-02-04

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT05225285. Inclusion in this directory is not an endorsement.